Equities

Mereo BioPharma Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mereo BioPharma Group PLC

Actions
  • Price (USD)0.4157
  • Today's Change0.044 / 11.78%
  • Shares traded6.32m
  • 1 Year change-85.52%
  • Beta0.2926
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.

  • Revenue in USD (TTM)500.00k
  • Net income in USD-41.57m
  • Incorporated2015
  • Employees36.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tscan Therapeutics Inc8.42m-142.60m52.89m146.00--0.3672--6.28-1.12-1.120.0662.540.0276----43,417.53-46.73-38.91-51.63-43.93-----1,692.96-735.59----0.1837---86.62---42.91--25.13--
Estrella Immunopharma Inc0.00-13.50m53.17m-----------0.3697-0.36970.00-0.26050.00-------371.99----------------------------------
Beyondspring Inc0.00-7.83m53.24m40.00---------0.1942-0.01480.00-0.788------0.00---61.84---81.30-------6,633.90------------35.26--123.69--
Kazia Therapeutics Ltd (ADR)80.59k-14.63m53.74m12.00------666.84-12.28-12.280.0561-3.620.0083--0.0571---149.76-64.49---99.77-----18,159.65-573.31---------95.0911.5822.69------
Instil Bio Inc0.00-75.08m54.19m14.00--0.45-----11.39-11.390.0017.760.00----0.00-31.00-34.59-32.06-36.59-------469,515.20---19.230.4127------52.50--116.55--
Metagenomi Therapeutics Inc30.91m-88.74m54.80m124.00--0.3072--1.77-2.39-2.390.83084.750.102--39.91153,034.70-29.27---33.42-------287.06------0.00--16.84---14.36------
Grace Therapeutics, Inc0.00-5.98m55.86m32.00--0.8608-----0.3607-0.36070.004.190.00-------9.22-24.13-9.46-25.07-------48,136.22----0.00------25.56------
Tevogen Bio Holdings Inc0.00-31.42m56.40m18.00---------0.2138-0.21380.00-0.03960.00----0.00-706.86-----------------231.10--------83.01------
PMV Pharmaceuticals Inc0.00-82.71m59.06m63.00--0.4861-----1.58-1.580.002.280.00----0.00-46.29-21.46-49.90-22.32------------0.00------14.87--43.14--
Mereo BioPharma Group plc - ADR500.00k-41.57m59.18m36.00--1.27--118.36-0.2629-0.26290.00320.29290.007--0.226513,888.89-58.41-59.10-68.08-71.6473.60---8,314.60-510.72----0.00---100.00---46.79--91.99--
RetinalGenix Technologies Inc0.00-2.67m59.54m0.00---------0.1455-0.14550.00-0.11680.00-------5,576.42-14,417.91---------------684.26---------106.65------
Annovis Bio Inc0.00-24.88m62.81m8.00--3.64-----1.41-1.410.000.65170.00----0.00-157.74-116.87-221.93-138.75------------0.00------56.25------
Fractyl Health Inc3.00k-122.20m64.17m107.00------21,390.29-2.27-2.270.00006-0.0240.00002----28.04-101.33-78.52-118.18-97.44100.00---4,073,233.00-122,747.90---31.401.12---22.50--25.29--78.65--
Adicet Bio Inc0.00-115.01m66.19m152.00--0.3294-----20.22-20.220.0020.980.00----0.00-59.52-36.24-66.08-39.41-------813.80----0.0088------17.90--32.77--
Data as of Feb 17 2026. Currency figures normalised to Mereo BioPharma Group PLC's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.